These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 25624048

  • 21. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
    Munugalavadla V, Mariathasan S, Slaga D, Du C, Berry L, Del Rosario G, Yan Y, Boe M, Sun L, Friedman LS, Chesi M, Leif Bergsagel P, Ebens A.
    Oncogene; 2014 Jan 16; 33(3):316-25. PubMed ID: 23318440
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chène P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, García-Echeverría C, Sellers WR, Voliva CF.
    Mol Cancer Ther; 2012 Feb 16; 11(2):317-28. PubMed ID: 22188813
    [Abstract] [Full Text] [Related]

  • 25. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss.
    Diamond P, Labrinidis A, Martin SK, Farrugia AN, Gronthos S, To LB, Fujii N, O'Loughlin PD, Evdokiou A, Zannettino AC.
    J Bone Miner Res; 2009 Jul 16; 24(7):1150-61. PubMed ID: 19335218
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest.
    Sadeghi S, Esmaeili S, Pourbagheri-Sigaroodi A, Safaroghli-Azar A, Bashash D.
    Turk J Haematol; 2020 Aug 28; 37(3):167-176. PubMed ID: 32160736
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
    Pereira JK, Machado-Neto JA, Lopes MR, Morini BC, Traina F, Costa FF, Saad ST, Favaro P.
    Eur J Cancer; 2015 Sep 28; 51(14):2076-85. PubMed ID: 26238016
    [Abstract] [Full Text] [Related]

  • 30. Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: An emerging mechanism of action of BKM120.
    Bashash D, Delshad M, Safaroghli-Azar A, Safa M, Momeny M, Ghaffari SH.
    Int J Biochem Cell Biol; 2017 Oct 28; 91(Pt A):1-8. PubMed ID: 28834761
    [Abstract] [Full Text] [Related]

  • 31. SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
    Heusschen R, Muller J, Binsfeld M, Marty C, Plougonven E, Dubois S, Mahli N, Moermans K, Carmeliet G, Léonard A, Baron F, Beguin Y, Menu E, Cohen-Solal M, Caers J.
    Oncotarget; 2016 May 24; 7(21):30712-29. PubMed ID: 27095574
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.
    Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, King P, Vande Broek I, De Raeve H, Van Camp B, Croucher P, Vanderkerken K.
    Leukemia; 2009 Oct 24; 23(10):1894-903. PubMed ID: 19494837
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease.
    Muller J, Bolomsky A, Dubois S, Duray E, Stangelberger K, Plougonven E, Lejeune M, Léonard A, Marty C, Hempel U, Baron F, Beguin Y, Cohen-Solal M, Ludwig H, Heusschen R, Caers J.
    Haematologica; 2018 Aug 24; 103(8):1359-1368. PubMed ID: 29748441
    [Abstract] [Full Text] [Related]

  • 36. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.
    Allegretti M, Ricciardi MR, Licchetta R, Mirabilii S, Orecchioni S, Reggiani F, Talarico G, Foà R, Bertolini F, Amadori S, Torrisi MR, Tafuri A.
    Sci Rep; 2015 Dec 17; 5():18137. PubMed ID: 26674543
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
    Dairaghi DJ, Oyajobi BO, Gupta A, McCluskey B, Miao S, Powers JP, Seitz LC, Wang Y, Zeng Y, Zhang P, Schall TJ, Jaen JC.
    Blood; 2012 Aug 16; 120(7):1449-57. PubMed ID: 22618707
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.